|
|
 |
Our research broadly involves the identification, significance,
and function of genetic mutations in pediatric leukemia. We develop
and use laboratory based assays to conduct cohort studies in primary
human cells that interrogate the role of specific genetic mutations in
human leukemia. We focus on integrating novel mutations into clinical use
(e.g. assessing prognostic significance or minimal residual disease) as well
as yield insights that lead to more scientific questions about the pathogenesis
and mechanisms of disease. Recent areas of interest have focused on using
phosphoflow signaling tools to dissect the aberrant signal transduction pathways
that arise in response to mutations in the Ras pathway in juvenile myelomonocytic
leukemia (JMML). In addition, we have begun to sort stem and progenitor cells
to further interrogate the population of cells that initiate and maintain JMML.
Selected Publications
Loh ML, Ahn P, Perez-Atayde AR, Gebhardt MC, Shamberger RE, Grier HE. Treatment of Infantile Fibrosarcoma with Neoadjuvant Chemotherapy:
Results from the Dana-Farber Cancer Institute and Children s Hospital, Boston. J. Pediatr Hematol Oncol. 2002; 24:722-726.
Loh ML, Vattikuti S, Reynolds MG, Carlson EJ, Schubbert S, Lieuw KH, Cheng JW, Stokoe D, Bonifas JM, Curtis NP, Gotlib J, Meshinchi S, LeBeau MM,
Emanuel P, Shannon KM. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004; 103(6): 2325-31
Loh ML, Reynolds MG, Vattikuti S, Gerbing R, Alonzo T, Carlson E, Cheng J, Lee C, Lange B, Meshinchi S. PTPN11 mutations in pediatric
AML: A report from the Children s Cancer Group Leukemia 2004; Nov;18(11):1831-4.
Information last updated September 2007
|
|
|
